Resveratrol inhibits the release of soluble fms-like tyrosine kinase (sFlt-1) from human placenta

Melissa J. Cudmore, Wenda Ramma, Meng Cai, Takeshi Fujisawa, Shakil Ahmad, Bahjat Al-Ani, Asif Ahmed

Research output: Contribution to journalArticle

Abstract

Objective - Soluble vascular endothelial growth factor receptor–1 (also know as soluble fms-like tyrosine kinase [sFlt]-1) is a key causative factor of preeclampsia. Resveratrol, a plant phytoalexin, has antiinflammatory and cardioprotective properties. We sought to determine the effect of resveratrol on sFlt-1 release.

Study Design - Human umbilical vein endothelial cells, transformed human trophoblast-8 (HTR/SVneo)-8/SVneo trophoblast cells, or placental explants were incubated with cytokines and/or resveratrol. Conditioned media were assayed for sFlt-1 by enzyme-linked immunosorbent assay and cell proteins used for Western blotting.

Results - Resveratrol inhibited cytokine-induced release of sFlt-1 from normal placental explants and from preeclamptic placental explants. Preincubation of human umbilical vein endothelial cells or HTR-8/SVneo cells with resveratrol abrogated sFlt-1 release. Resveratrol prevented the up-regulation of early growth response protein-1 (Egr-1), a transcription factor necessary for induction of the vascular endothelial growth factor receptor–1 gene and caused up-regulation of heme oxygenase–1, a cytoprotective enzyme found to be dysfunctional in preeclampsia.

Conclusion - In summary, resveratrol can inhibit sFlt-1 release and up-regulate heme oxygenase–1; thus, may offer therapeutic potential in preeclampsia.
LanguageEnglish
Pages253.e10–253.e15
Number of pages6
JournalAmerican Journal of Obstetrics and Gynecology
Volume206
Issue number3
DOIs
Publication statusPublished - Mar 2012

Fingerprint

Vascular Endothelial Growth Factor Receptor-1
Placenta
Pre-Eclampsia
Heme Oxygenase-1
Up-Regulation
Human Umbilical Vein Endothelial Cells
Trophoblasts
Early Growth Response Protein 1
Cytokines
resveratrol
Conditioned Culture Medium
Anti-Inflammatory Agents
Transcription Factors
Western Blotting
Enzyme-Linked Immunosorbent Assay

Keywords

  • endothelial cells
  • heme oxygenase–1
  • placenta
  • resveratrol
  • soluble fms-like tyrosine kinase–1

Cite this

Cudmore, Melissa J. ; Ramma, Wenda ; Cai, Meng ; Fujisawa, Takeshi ; Ahmad, Shakil ; Al-Ani, Bahjat ; Ahmed, Asif. / Resveratrol inhibits the release of soluble fms-like tyrosine kinase (sFlt-1) from human placenta. In: American Journal of Obstetrics and Gynecology. 2012 ; Vol. 206, No. 3. pp. 253.e10–253.e15.
@article{f3238f18c7e04550945764e0542f1011,
title = "Resveratrol inhibits the release of soluble fms-like tyrosine kinase (sFlt-1) from human placenta",
abstract = "Objective - Soluble vascular endothelial growth factor receptor–1 (also know as soluble fms-like tyrosine kinase [sFlt]-1) is a key causative factor of preeclampsia. Resveratrol, a plant phytoalexin, has antiinflammatory and cardioprotective properties. We sought to determine the effect of resveratrol on sFlt-1 release.Study Design - Human umbilical vein endothelial cells, transformed human trophoblast-8 (HTR/SVneo)-8/SVneo trophoblast cells, or placental explants were incubated with cytokines and/or resveratrol. Conditioned media were assayed for sFlt-1 by enzyme-linked immunosorbent assay and cell proteins used for Western blotting.Results - Resveratrol inhibited cytokine-induced release of sFlt-1 from normal placental explants and from preeclamptic placental explants. Preincubation of human umbilical vein endothelial cells or HTR-8/SVneo cells with resveratrol abrogated sFlt-1 release. Resveratrol prevented the up-regulation of early growth response protein-1 (Egr-1), a transcription factor necessary for induction of the vascular endothelial growth factor receptor–1 gene and caused up-regulation of heme oxygenase–1, a cytoprotective enzyme found to be dysfunctional in preeclampsia.Conclusion - In summary, resveratrol can inhibit sFlt-1 release and up-regulate heme oxygenase–1; thus, may offer therapeutic potential in preeclampsia.",
keywords = "endothelial cells, heme oxygenase–1, placenta, resveratrol, soluble fms-like tyrosine kinase–1",
author = "Cudmore, {Melissa J.} and Wenda Ramma and Meng Cai and Takeshi Fujisawa and Shakil Ahmad and Bahjat Al-Ani and Asif Ahmed",
year = "2012",
month = "3",
doi = "10.1016/j.ajog.2011.11.010",
language = "English",
volume = "206",
pages = "253.e10–253.e15",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Elsevier",
number = "3",

}

Resveratrol inhibits the release of soluble fms-like tyrosine kinase (sFlt-1) from human placenta. / Cudmore, Melissa J.; Ramma, Wenda; Cai, Meng; Fujisawa, Takeshi; Ahmad, Shakil; Al-Ani, Bahjat; Ahmed, Asif.

In: American Journal of Obstetrics and Gynecology, Vol. 206, No. 3, 03.2012, p. 253.e10–253.e15.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Resveratrol inhibits the release of soluble fms-like tyrosine kinase (sFlt-1) from human placenta

AU - Cudmore, Melissa J.

AU - Ramma, Wenda

AU - Cai, Meng

AU - Fujisawa, Takeshi

AU - Ahmad, Shakil

AU - Al-Ani, Bahjat

AU - Ahmed, Asif

PY - 2012/3

Y1 - 2012/3

N2 - Objective - Soluble vascular endothelial growth factor receptor–1 (also know as soluble fms-like tyrosine kinase [sFlt]-1) is a key causative factor of preeclampsia. Resveratrol, a plant phytoalexin, has antiinflammatory and cardioprotective properties. We sought to determine the effect of resveratrol on sFlt-1 release.Study Design - Human umbilical vein endothelial cells, transformed human trophoblast-8 (HTR/SVneo)-8/SVneo trophoblast cells, or placental explants were incubated with cytokines and/or resveratrol. Conditioned media were assayed for sFlt-1 by enzyme-linked immunosorbent assay and cell proteins used for Western blotting.Results - Resveratrol inhibited cytokine-induced release of sFlt-1 from normal placental explants and from preeclamptic placental explants. Preincubation of human umbilical vein endothelial cells or HTR-8/SVneo cells with resveratrol abrogated sFlt-1 release. Resveratrol prevented the up-regulation of early growth response protein-1 (Egr-1), a transcription factor necessary for induction of the vascular endothelial growth factor receptor–1 gene and caused up-regulation of heme oxygenase–1, a cytoprotective enzyme found to be dysfunctional in preeclampsia.Conclusion - In summary, resveratrol can inhibit sFlt-1 release and up-regulate heme oxygenase–1; thus, may offer therapeutic potential in preeclampsia.

AB - Objective - Soluble vascular endothelial growth factor receptor–1 (also know as soluble fms-like tyrosine kinase [sFlt]-1) is a key causative factor of preeclampsia. Resveratrol, a plant phytoalexin, has antiinflammatory and cardioprotective properties. We sought to determine the effect of resveratrol on sFlt-1 release.Study Design - Human umbilical vein endothelial cells, transformed human trophoblast-8 (HTR/SVneo)-8/SVneo trophoblast cells, or placental explants were incubated with cytokines and/or resveratrol. Conditioned media were assayed for sFlt-1 by enzyme-linked immunosorbent assay and cell proteins used for Western blotting.Results - Resveratrol inhibited cytokine-induced release of sFlt-1 from normal placental explants and from preeclamptic placental explants. Preincubation of human umbilical vein endothelial cells or HTR-8/SVneo cells with resveratrol abrogated sFlt-1 release. Resveratrol prevented the up-regulation of early growth response protein-1 (Egr-1), a transcription factor necessary for induction of the vascular endothelial growth factor receptor–1 gene and caused up-regulation of heme oxygenase–1, a cytoprotective enzyme found to be dysfunctional in preeclampsia.Conclusion - In summary, resveratrol can inhibit sFlt-1 release and up-regulate heme oxygenase–1; thus, may offer therapeutic potential in preeclampsia.

KW - endothelial cells

KW - heme oxygenase–1

KW - placenta

KW - resveratrol

KW - soluble fms-like tyrosine kinase–1

UR - http://www.scopus.com/inward/record.url?scp=84857792906&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2011.11.010

DO - 10.1016/j.ajog.2011.11.010

M3 - Article

VL - 206

SP - 253.e10–253.e15

JO - American Journal of Obstetrics and Gynecology

T2 - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 3

ER -